sulfotransferase family, cytosolic, 1C, member 2 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored SULT1C2P2 profile across patient tissues and cancer cell-line models. SULT1C2P2 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, SULT1C2P2 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, SULT1C2P2 RNA expression shows 9,098 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight LUSC, COAD, and ESCA as cancer lineages where SULT1C2P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SULT1C2P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SULT1C2P2 survival associations across molecular data types. SULT1C2P2 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SULT1C2P2 RNA expression–survival associations across cancer types. High SULT1C2P2 expression shows unfavorable associations in LUSC, ACC, THYM, TGCT and UCEC, but favorable associations in STAD. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .019). Together, the overview and detailed table identify LUSC as the clearest survival context for SULT1C2P2 RNA expression.
This table summarizes SULT1C2P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SULT1C2P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SULT1C2P2 shows lower tumor expression in STAD and higher tumor expression in COAD, KIRC, READ, LIHC and LUAD. The COAD box plot shows higher SULT1C2P2 RNA expression in tumor versus normal tissue (log2 FC = +0.187, t-test p = .001).
This table shows molecular features associated with SULT1C2P2 in patient tissues and cancer cell lines. In patient samples, SULT1C2P2 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
